Analysts Set Oculis Holding AG (NASDAQ:OCS) Target Price at $38.33

Shares of Oculis Holding AG (NASDAQ:OCS) have been assigned an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $38.3333.

OCS has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Needham & Company LLC cut their price objective on Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Wall Street Zen lowered Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Guggenheim cut their price objective on Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Finally, JPMorgan Chase & Co. cut their price objective on Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 3rd.

Institutional Investors Weigh In On Oculis

Several hedge funds have recently made changes to their positions in OCS. Geode Capital Management LLC boosted its position in shares of Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Oculis during the second quarter valued at approximately $393,000. Bank of America Corp DE boosted its position in shares of Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after purchasing an additional 878 shares in the last quarter. Woodline Partners LP boosted its position in shares of Oculis by 65.8% during the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after purchasing an additional 33,265 shares in the last quarter. Finally, Aventura Private Wealth LLC bought a new stake in shares of Oculis during the fourth quarter valued at approximately $80,000. 22.30% of the stock is currently owned by institutional investors.

Oculis Price Performance

Shares of OCS stock opened at $11.45 on Wednesday. The firm has a market cap of $663.87 million, a P/E ratio of -5.38 and a beta of 0.23. Oculis has a fifty-two week low of $10.52 and a fifty-two week high of $34.47. The business’s 50 day moving average price is $24.38 and its 200-day moving average price is $24.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The business had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. On average, equities research analysts anticipate that Oculis will post -2.27 earnings per share for the current year.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.